Paradigm Biopharmaceuticals Ltd, informed the market that its CEO, Paul Rennie, is transitioning from his executive role (Managing Director) to a non-executive role (Chairman) with immediate effect. Mr. Rennie founded the Company in 2014 and has overseen its progress from a privately operated business to a Phase 3 clinical development ASX 300 Company. Effective immediately, Dr. Donna Skerrett, the Company's Chief Medical Officer, will be appointed the interim CEO. The Board's Remuneration and Nominations Committee have engaged a global executive search firm which is undertaking the search for the new CEO.